US Patent 7667021 Neutralizing human anti-IGFR antibody
Patent 7667021 was granted and assigned to Schering on February, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+269 characters)
Article
Patent abstract
The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07667021 Neutralizing human anti-IGFR antibody US Patent 7667021 Neutralizing human anti-IGFR antibody
Infobox
Patent Number
0766702100
Patent Number
766702100
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076670210
Date of Patent
February 23, 2010
0Patent Application Number
115986180
Date Filed
November 13, 2006
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076670210
Date of Patent
February 23, 2010
0Patent Application Number
115986180
Date Filed
November 13, 2006
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07667021 Neutralizing human anti-IGFR antibody
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07667021
Date of patent
February 23, 2010
Patent application number
11598618
Date Filed
November 13, 2006
Patent primary examiner
Find more entities like US Patent 7667021 Neutralizing human anti-IGFR antibody
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
